FDA panel recommends approval of FS069

Article

A Food and Drug Administration advisory committee last week recommendedthe approval of FS069, a second-generation ultrasound contrastagent developed by Molecular Biosystems of San Diego. The productnow awaits a final decision by the FDA, which could come

A Food and Drug Administration advisory committee last week recommendedthe approval of FS069, a second-generation ultrasound contrastagent developed by Molecular Biosystems of San Diego. The productnow awaits a final decision by the FDA, which could come in thenext several months.

The action by the Radiology Device Advisory Panel comes onlymonths after FS069's premarket approval application was filedby MBI and its U.S. marketing partner for the agent, Mallinckrodtof St. Louis (SCAN 11/6/96). FS069's path through the FDA approvalprocess has been considerably shorter than MBI's previous contrastagent, Albunex, which underwent nearly four years of PMA reviewbefore it was finally approved by the agency in 1994 (SCAN 8/31/94).

Industry analysts believe that FS069 has much more potentialthan Albunex, which was the first ultrasound contrast agent onthe U.S. market. Sales of Albunex have been disappointing, dueto its short duration and the complexity required to handle theproduct.

FS069 is designed to enhance visualization of endocardial borderdelineation and left ventricular opacification during echocardiographyexams. This capability is important in diagnosing regional andglobal wall-motion abnormalities, which may be a measure of theseverity of coronary artery disease. The advisory committee alsorecommended approval of FS069 for enhancing Doppler signals. MBIplans to pursue additional cardiac imaging capabilities for FS069,including myocardial perfusion and enhancement of liver and kidneyultrasound imaging.

In making its decision, the advisory panel took the positionthat the data supporting the safety and effectiveness of FS069were so compelling that the agent was recommended to the FDA withoutconditions, including no postmarket surveillance follow-up.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.